Depomed Stock Price Target and Analyst Ratings (NASDAQ:DEPO)

Analyst Price Target for DEPO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Depomed in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.30.

N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Depomed. This rating has held steady since July 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/8/2019

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/7/2019

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/6/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/4/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/2/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/1/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/30/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/1/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
8/8/2018	Royal Bank of Canada	Set Price Target	Hold	$8.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
7/9/2018	Janney Montgomery Scott	Upgrade	Neutral ➝ Buy	$7.00 ➝ $10.00	Medium	i
3/23/2018	Mizuho	Reiterated Rating	Buy	$9.00	High	i
3/2/2018	Roth Capital	Set Price Target	Buy	$10.00	Medium	i Rating by Scott Henry at Roth Capital
3/1/2018	Piper Jaffray Companies	Reiterated Rating	Hold	$8.00	Medium	i Rating by David Amsellem at Piper Jaffray Companies
12/7/2017	Royal Bank of Canada	Set Price Target	Hold	$9.00	Medium	i Rating by Randall Stanicky at Royal Bank of Canada
12/7/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$9.00	High	i Rating by David Amsellem at Piper Jaffray Companies
12/5/2017	Mizuho	Upgrade	Neutral ➝ Buy	$9.00	High	i
11/10/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$5.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
11/10/2017	UBS Group	Boost Price Target	Neutral	$6.00 ➝ $7.00	N/A	i
11/9/2017	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight		N/A	i
11/8/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$8.00 ➝ $6.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
10/27/2017	Royal Bank of Canada	Set Price Target	Hold	$8.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
10/20/2017	Royal Bank of Canada	Set Price Target	Hold	$10.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
10/15/2017	Piper Jaffray Companies	Set Price Target	Hold	$9.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
10/13/2017	Mizuho	Reiterated Rating	Neutral	$11.00 ➝ $6.00	N/A	i
9/10/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$9.00	High	i
8/9/2017	Piper Jaffray Companies	Reiterated Rating	Neutral	$10.00 ➝ $9.00	Medium	i
8/8/2017	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$12.00 ➝ $5.00	High	i
8/8/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$13.00 ➝ $10.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
8/8/2017	Janney Montgomery Scott	Downgrade	Buy ➝ Neutral	$18.00 ➝ $8.00	High	i
7/16/2017	Royal Bank of Canada	Set Price Target	Hold	$13.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
6/13/2017	Royal Bank of Canada	Reiterated Rating	Hold	$13.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
5/25/2017	Mizuho	Lower Price Target	Neutral	$13.00 ➝ $11.00	Medium	i
5/15/2017	Cantor Fitzgerald	Set Price Target	Hold	$14.00	Medium	i Rating by Chiara Russo at Cantor Fitzgerald
5/10/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$19.00 ➝ $13.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
5/10/2017	Piper Jaffray Companies	Upgrade	Underweight ➝ Neutral	$11.00 ➝ $10.00	High	i Rating by David Amsellem at Piper Jaffray Companies
4/11/2017	Janney Montgomery Scott	Reiterated Rating	Buy	$26.00	Low	i
3/30/2017	JMP Securities	Reiterated Rating	Outperform	$30.00 ➝ $16.00	High	i
3/29/2017	Janney Montgomery Scott	Reiterated Rating	Buy	$26.00	High	i
3/29/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$22.00 ➝ $19.00	High	i Rating by Randall Stanicky at Royal Bank of Canada
3/29/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$19.00	High	i Rating by Chiara Russo at Cantor Fitzgerald
3/29/2017	Mizuho	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $13.00	Low	i
3/25/2017	Royal Bank of Canada	Set Price Target	Hold	$22.00	Low	i Rating by Randall Stanicky at Royal Bank of Canada
3/1/2017	Cantor Fitzgerald	Set Price Target	Hold	$23.00 ➝ $19.00	N/A	i Rating by Chiara Russo at Cantor Fitzgerald
2/27/2017	Janney Montgomery Scott	Reiterated Rating	Buy		N/A	i
2/23/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$22.00	N/A	i
2/20/2017	Mizuho	Downgrade	Buy ➝ Neutral		N/A	i
2/18/2017	Roth Capital	Set Price Target	Buy	$24.00	N/A	i Rating by Scott Henry at Roth Capital
2/14/2017	Mizuho	Downgrade	Buy ➝ Neutral	$24.00 ➝ $17.00	N/A	i
1/11/2017	Cantor Fitzgerald	Set Price Target	Hold	$23.00	N/A	i Rating by Chiara Russo at Cantor Fitzgerald
12/12/2016	Roth Capital	Set Price Target	Buy	$27.00	N/A	i Rating by Scott Henry at Roth Capital
12/12/2016	Piper Jaffray Companies	Downgrade	Neutral ➝ Underweight	$17.00 ➝ $14.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
12/4/2016	Roth Capital	Set Price Target	Buy	$27.00	N/A	i Rating by Scott Henry at Roth Capital
11/28/2016	Roth Capital	Set Price Target	Buy	$27.00	N/A	i Rating by Scott Henry at Roth Capital
11/9/2016	Mizuho	Upgrade	Neutral ➝ Buy	$27.00 ➝ $24.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
11/8/2016	SVB Leerink	Set Price Target	Buy	$22.00	N/A	i Rating by Jason Gerberry at SVB Leerink LLC
11/8/2016	Mizuho	Reiterated Rating	Hold	$27.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
11/8/2016	Cantor Fitzgerald	Downgrade	Buy ➝ Hold	$25.00 ➝ $23.00	N/A	i Rating by chiara russo at Cantor Fitzgerald
10/30/2016	Roth Capital	Set Price Target	Buy	$28.00	N/A	i Rating by Scott Henry at Roth Capital
10/21/2016	Roth Capital	Set Price Target	Buy	$28.00	N/A	i Rating by Scott Henry at Roth Capital
10/18/2016	Mizuho	Reiterated Rating	Hold	$27.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
10/17/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$31.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
10/4/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00 ➝ $31.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
10/4/2016	Mizuho	Downgrade	Buy ➝ Neutral		N/A	i Rating by Irina Rivkind Koffler at Mizuho
10/3/2016	Mizuho	Downgrade	Buy ➝ Neutral	$27.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
10/3/2016	UBS Group	Reiterated Rating	Neutral	$20.00 ➝ $26.00	N/A	i Rating by Ami Fadia at UBS Group AG
10/2/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Jason Gerberry at SVB Leerink LLC
9/28/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
9/23/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$22.00	N/A	i
9/16/2016	Mizuho	Boost Price Target	Buy	$23.00 ➝ $27.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
9/14/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
8/11/2016	Cantor Fitzgerald	Reiterated Rating	Buy		N/A	i Rating by Chiara Russo at Cantor Fitzgerald
8/4/2016	Piper Jaffray Companies	Reiterated Rating	Neutral	$18.00 ➝ $19.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
8/4/2016	JMP Securities	Lower Price Target	Market Outperform	$28.00 ➝ $22.00	N/A	i
8/4/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
8/4/2016	Mizuho	Reiterated Rating	Buy	$23.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
7/28/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$26.00	N/A	i Rating by Chiara Russo at Cantor Fitzgerald
7/27/2016	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$21.00 ➝ $18.00	N/A	i
7/21/2016	Mizuho	Reiterated Rating	Positive		N/A	i Rating by Irina Rivkind Koffler at Mizuho
7/19/2016	Cantor Fitzgerald	Reiterated Rating	Buy		N/A	i Rating by Chiara Russo at Cantor Fitzgerald
7/18/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
7/18/2016	SVB Leerink	Reiterated Rating	Positive		N/A	i Rating by Jason Gerberry at SVB Leerink LLC
7/11/2016	Royal Bank of Canada	Reiterated Rating	Hold		N/A	i Rating by Randall Stanicky at Royal Bank of Canada
7/8/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
7/7/2016	UBS Group	Downgrade	Buy ➝ Neutral	$20.00	N/A	i Rating by Ami Fadia at UBS Group AG
6/26/2016	Mizuho	Reiterated Rating	Buy		N/A	i Rating by Irina Rivkind Koffler at Mizuho
6/22/2016	Cantor Fitzgerald	Reiterated Rating	Buy		N/A	i Rating by Chiara Russo at Cantor Fitzgerald
6/15/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
5/27/2016	Mizuho	Boost Price Target	Buy	$19.00 ➝ $23.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
5/26/2016	Janney Montgomery Scott	Boost Price Target	Neutral ➝ Hold	$20.13 ➝ $28.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
5/24/2016	UBS Group	Reiterated Rating	Buy	$20.00	N/A	i Rating by Ami Fadia at UBS Group AG
5/17/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
5/9/2016	Mizuho	Upgrade	Neutral ➝ Buy	$18.00 ➝ $19.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
5/8/2016	Mizuho	Upgrade	Neutral ➝ Buy	$18.00 ➝ $19.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
5/8/2016	Cantor Fitzgerald	Reiterated Rating	Buy		N/A	i Rating by Chiara Russo at Cantor Fitzgerald
5/6/2016	Piper Jaffray Companies	Lower Price Target	Overweight	$23.00 ➝ $21.00	N/A	i
5/2/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$22.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
4/26/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$26.00	N/A	i Rating by Chiara Russo at Cantor Fitzgerald
4/16/2016	SVB Leerink	Reiterated Rating	Outperform		N/A	i Rating by Jason Gerberry at SVB Leerink LLC
4/12/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A	i Rating by Ken Trbovich at Janney Montgomery Scott
4/11/2016	Mizuho	Boost Price Target	Neutral	$14.00 ➝ $18.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
4/10/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$26.00	N/A	i Rating by Chiara Russo at Cantor Fitzgerald
4/9/2016	Mizuho	Reiterated Rating	Neutral	$14.00 ➝ $18.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
3/29/2016	SVB Leerink	Reiterated Rating	Outperform		N/A	i Rating by Jason Gerberry at SVB Leerink LLC
3/29/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$26.00	N/A	i Rating by Chiara Russo at Cantor Fitzgerald
3/28/2016	Roth Capital	Reiterated Rating	Buy		N/A	i Rating by Scott Henry at Roth Capital
3/25/2016	Royal Bank of Canada	Lower Price Target		$24.00 ➝ $22.00	N/A	i Rating by Randall Stanicky at Royal Bank of Canada
3/24/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$23.00	N/A	i
3/24/2016	Northland Securities	Initiated Coverage	Outperform	$22.00	N/A	i
3/24/2016	Mizuho	Lower Price Target	Neutral	$16.00 ➝ $14.00	N/A	i Rating by Irina Rivkind Koffler at Mizuho
3/10/2016	SVB Leerink	Reiterated Rating	Outperform		N/A	i Rating by J. Gerberry at SVB Leerink LLC
3/10/2016	SVB Leerink	Initiated Coverage	Outperform	$21.00	N/A	i

(Data available from 3/2/2016 forward)

Assertio Holdings, Inc. operates as a holding company. The firm develops pharmaceuticals. It engages in the provision of solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Today's Range

Now: $7.30

$7.09

$7.42

50 Day Range

MA: N/A

52 Week Range

Now: $7.30

$4.31

$9.48

Volume

940,193 shs

Average Volume

1,300,311 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Depomed?

The following equities research analysts have issued reports on Depomed in the last twelve months:
View the latest analyst ratings for DEPO.

What is the current price target for Depomed?

0 Wall Street analysts have set twelve-month price targets for Depomed in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Depomed in the next year.
View the latest price targets for DEPO.

What is the current consensus analyst rating for Depomed?

Depomed currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DEPO.

What other companies compete with Depomed?

Other companies that are similar to Depomed include Johnson & Johnson, Eli Lilly and, AbbVie, Pfizer, Merck & Co., Inc., Bristol-Myers Squibb, Zoetis, Horizon Therapeutics Public, Royalty Pharma, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Pacira BioSciences, Corcept Therapeutics and Endo International.

How do I contact Depomed's investor relations team?

Depomed's physical mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company's listed phone number is (224) 419-7106 and its investor relations email address is [email protected] The official website for Depomed is www.depomedinc.com.

NASDAQ:DEPO - Depomed Stock Price Target and Predictions

Analyst Price Target for DEPO

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Depomed?

What is the current price target for Depomed?

What is the current consensus analyst rating for Depomed?

What other companies compete with Depomed?

How do I contact Depomed's investor relations team?